Aggressive Management for $LPTX and Fraud in Alzheimer's and $SAVA

Biotech Bros

English - August 01, 2022 12:00 - 1 hour - 42.7 MB
Investing Business Health & Fitness Medicine biotech investing money finance get rich markets comedy health healthcare Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Acquisitions in the $XBI, a Second Chance at bat for $AMLX, and a Potential Cure for Huntington's

Next Episode: Things Looking Green for $XBI and Alnylam Pharmaceuticals

This week on the podcast Agustin discusses Leap Therapeutics and their R&D day as well as the news that Novartis is discontinuing their PD-L1 submission for NSCLC and finally he sheds light on a scandal that is rocking neuroscience research and Alzheimer's drug development.

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

Twitter Mentions

@biotech_bros